SELLAS Life Sciences Shares Surge After Leukemia Vaccine Trial Results
· 3 sources
SELLAS Life Sciences stock jumped sharply after the company reported its leukemia vaccine extended survival in a Phase 3 trial, per Quantisnow and NewsBytes.
What happened
Shares of SELLAS Life Sciences Group (SLS) rose sharply after the company announced results from a Phase 3 trial of its leukemia vaccine, according to Quantisnow and NewsBytes. The company said the vaccine extended survival.
Quantisnow reports the stock gained 157%, while one NewsBytes article cites a 156% rise. A second NewsBytes report puts the surge at 233%. The differing figures likely reflect different points in trading, though the sources do not explain the gap.
NewsBytes links the move to results from a trial in AML, a form of leukemia, and describes the data as cancer vaccine results.
Context
Late-stage clinical trial results often cause large share price swings for small biotechnology companies, since a single product can account for much of their value.
Why it matters
The reaction shows how much investors weigh pivotal trial data for SELLAS, whose outlook is closely tied to its leukemia vaccine program.
Stocks in this story
Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.
39%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $11.63 and $21.50; 9 in 10, between $6.74 and $37.08.
Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy